Dogecoin’s Price Potential: Breakout or Breakdown?by John Darbie 12.02.2024Dogecoin, the largest meme coin, could break out of its trading range with support at $0.075 and resistance at $0.088. ...
Bitcoin Surges Past $50K: Two-Year High Triumphby John Darbie 12.02.2024Bitcoin surges past $50,000 for the first time in over two years, driven by anticipation of interest rate cuts and ...
VF Corp Stock Surges Amid CEO Buy & Activist Pressureby Terry Bingman 12.02.2024VF Corp. saw its stock soar 13% on positive news amidst activist investor pressure. CEO's stock purchase and support from ...
Spectral AI: Surgeon Appointment Boosts Boardby Lilu Anderson 12.02.2024Spectral AI has appointed Dr. J. Michael DiMaio to its Board of Directors as a non-executive member. This move strengthens ...
Beacon Acquires Metro Sealant: Expanding Waterproofing Servicesby Mark Eisenberg 12.02.2024Beacon has completed its acquisition of Metro Sealant & Waterproofing, expanding its services in the waterproofing sector. This aligns with ...
Starbucks Valentine’s Drinks: Hit or Miss?by Lilu Anderson 12.02.2024Starbucks introduces two delicious Valentine's Day drinks - Chocolate Hazelnut Cookie Cold Brew and Chocolate-Covered Strawberry Crème Frappuccino. These limited-time ...
Traders Hedge as U.S. Vote Nears: Stock Market Braceby Terry Bingman 12.02.2024Investors are preparing for potential market turbulence surrounding the US presidential election, with demand for options increasing earlier than in ...
Immutable and LiquidX Power Up Pixelmon’s Comebackby John Darbie 12.02.2024Pixelmon, the popular game known for its NFT creature sale, is partnering with Immutable to launch on the zkEVM blockchain. ...
2024’s Investment Darling: Surprising Industry Revealedby Terry Bingman 12.02.2024Investment newsletters have revealed their top picks for 2024, but the favored industry remains a mystery. With competition increasing, the ...
AN2 Therapeutics Phase 3 Trial Pause Impacts Stockby Mark Eisenberg 12.02.2024AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...